Creating a leading global quality and innovation-led CDMO in cell and gene therapy
Interim results for the six months ended 30 June 2023
September 2023
Forward looking statements
This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the "Securities"). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford Biomedica plc (the "Company") or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.
This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.
2
Delivering long-term sustainable growth
3
Pillar Plan
1 | 2 | 3 | |
Strong | Clear path towards | ||
implementation | |||
Clear strategy | profitability | ||
plan | |||
3
1 Clear strategy: accelerating towards becoming the leading pure-play CDMO in cell and gene therapy
- Transformation to a pure-play CDMO in an attractive high-growth market
- Quality and innovation-led with an unmatched track record in lentiviral vectors
- Proven and differentiated platform technologies
- Multi-vectorapproach with expertise in all key viral vector types
- Global footprint with a multi-site model
- A unified and global company with scalable operations
Total Addressable Market for outsourced viral vector supply is expected to be $3.8bn by 2028
# of | OXB | |
2028 TAM, | pipeline | growth |
22-'28 CAGR | assets | opportunity |
AAV | c.$2.9bn | 513 | |
+22% | |||
Integrating | c.$0.8bn | 244 | |
(Lentivirus | |||
and γ- | +18% | ||
retroviral) | |||
Adenovirus | c.<$0.5bn | 125 | |
-24% | |||
Source: Company data and third party research: Citeline | 4 |
2 A strong implementation plan that aligns operations with strategy shows first significant results
-
Significantly expanded commercial team
to leverage the growing pipeline of opportunities - Adapting structure and processes for improved efficiency and scalability
- Planned introduction of lenti in Boston by Q1/24 and AAV in Oxford as a next step
- Proposed acquisition: New hub in France to address client demand and to provide multi-vector capabilities
Oxford, UK | ||||
Boston, MA | Strasbourg, France | |||
Lyon, France | ||||
- Broadens footprint into Europe with facilities in Lyon and Strasbourg, France
- Provides flexibility with supply across borders in Europe
- Immediately revenue accretive (cash flow neutral)
5
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Oxford BioMedica plc published this content on 21 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 October 2023 15:52:27 UTC.